FINNENCE ▪ THE WIRE FILE
THE WIRE · № 61018
Price move▼ Bearish
Johnson & Johnson -2.3%
KINDPrice move
DIRECTION▼ Bearish
SOURCES1
ENTITIES3
STORY SIZESTANDALONE
FIRST SEEN2026-10-02 01:49 UTC
LAST UPDATE2026-10-02 01:49 UTC
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
J&J weakness drags healthcare, hinting at litigation or drug-pricing concerns.
J&J slides, weighing on healthcare
CATALYST TO WATCH
Litigation and drug-pricing headlines
MAIN RISK
Legal setbacks could deepen the drop
FULL DISPATCH
Johnson & Johnson (JNJ) moved -2.3% in the latest period (1d). Close: 258.66, prior: 264.74.
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
←CORRELATIONshares Healthcare
New Phase 3 trial: A Phase 3 Study of Inebilizumab in Participants With Primary Membranous Nephropathy — Amgen2026-10-01 12:00 UTC
New Phase 3 trial: A Phase 3 Study of Inebilizumab in Participants With Primary Membranous Nephropathy — Amgen2026-10-01 12:00 UTC
←CORRELATIONshares Healthcare
New Phase 3 trial: Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Homologous Recombination Deficiency (HRD) Negative Advanced Epithelial Ovarian Cancer — AstraZeneca2026-10-01 12:00 UTC
New Phase 3 trial: Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Homologous Recombination Deficiency (HRD) Negative Advanced Epithelial Ovarian Cancer — AstraZeneca2026-10-01 12:00 UTC
←CORRELATIONshares Healthcare
New Phase 3 trial: A Phase 3 Study of [177Lu]Ludotadipep for Metastatic Castration-Resistant Prostate Cancer — FutureChem2026-10-01 12:00 UTC
New Phase 3 trial: A Phase 3 Study of [177Lu]Ludotadipep for Metastatic Castration-Resistant Prostate Cancer — FutureChem2026-10-01 12:00 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.